Keywords
mometasone furoate
methylprednisolone aceponate
prednicarbate
How to Cite
Abstract
The problem of choosing the optimal glucocorticoids for topical use regularly arises for any physician involved in the treatment of dermatological diseases. When solving this problem, the doctor should take into account the nature, severity and localization of the pathological process, the patient's age, as well as the potency and the safety profile of the drug itself. One of the most common approaches to making the optimal choice of glucocorticoids for topical use, which is designed to reduce potential risks, involves administration the least active drugs at the beginning of the treatment, if they are ineffective, they switch to the use of more active drugs, and further the most active drugs. An obvious disadvantage of this approach is the duration of the procedure of the empirical selection of the drug, which can significantly impede treatment. The emergence of VI generation glucocorticoids, such as mometasone furoate, methylprednisolone aceponate and prednicarbate. The therapeutic potential of these drugs combines high activity and safety of use. It has changed the situation significantly and helped to solve the problem of the safe use of glucocorticoid drugs in pediatric and geriatric practice for the treatment of severe forms of dermatological diseases wich requires administration of the active glucocorticoids. The paper contains an overview of the main classification systems that are applied to glucocorticoids intended for use in dermatological practice, and a short analysis of literary data regarding the experience of the clinical use of VI generation glucocorticoids. The article also contains a retrospective overview of development of main approaches to improving the pharmacotherapeutic properties of topical glucocorticoids. Special attention is paid on the analysis of the influence of peculiarities of the chemical structure of drugs into pharmacokinetic and pharmacodynamic parameters.
Keywords: corticosteroid-responsive dermatoses, mometasone furoate, methylprednisolone aceponate, prednicarbate.
References
Aung T, Aung ST. Selection of an effective topical corticosteroid. Australian Journal of General Practice. 2021;50(9):651-5 DOI: 10.31128/AJGP-07-20-5507. PMID: 34462770.
Devaraj NK, Aneesa AR, Abdul Hadi AM, Shaira N. Topical corticosteroids in clinical practice. Medical journal of Malaysia. 2019;74(2):187-9. Available at: https://e-mjm.org/2019/v74n2/topical-corticosteroids.pdf
Gabros S, Nessel TA, Zito PM. Topical Corticosteroids. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 [update 7 Mar 2023]. Available at: https://www.ncbi.nlm.nih.gov/books/NBK532940/
Ference JD, Last AR. Choosing topical corticosteroids. American Family Physician. 2009;79(2):135-40. Available at: https://www.aafp.org/pubs/afp/issues/2009/0115/p135.pdf
Kaliuzhna LD. Mistse topichnykh hliukokortykoidiv u likuvanni dermatytiv riznoi etiolohii [The place of topical glucocorticoids in the treatment of dermatitis of various etiologies]. Zdorovia zhinky [Helth of woman]. 2016.8(114):33-6. Available at: http://nbuv.gov.ua/UJRN/Zdzh_2016_8_7 [in Ukrainian].
State Register of Medicinal Products of Ukraine. Ministry of Health of Ukraine. Available at: http://www.drlz.com.ua/ [in Ukrainian].
Andrashko YuV, Halnykina SO. The up-to-date conception ofthe optimal topical steroid therapy Ukrainian Journal of Dermatology, Venereology, Cosmetology. 2006;4:38-41. Available at: http://www.vitapol.com.ua/user_files/pdfs/uzdvk/206168276032350_27092009193753.pdf [in Ukrainian].
Mehta AB, Nadkarni NJ, Patil SP, Godse KV, Gautam M, Agarwal S. Topical corticosteroids in dermatology. Indian Journal of Dermatology, Venereology, and Leprolog. 2016;82(4):371-8. DOI: 10.4103/0378-6323.178903. PMID: 27279294.
Compendium 2019 – medicines. Ed. Kovalenko VM. Kiev: MORION; 2019. 2480 p. Available at: https://compendium.com.ua/uk/ [in Ukrainian].
Brogden RN, Pinder RM, Sawyer PR, Speight TM, Avery GS. Hydrocortisone 17-Butyrate: A New Topical Corticosteroid Preliminary Report. Drugs. 1976;12(4):249-57. DOI: 10.2165/00003495-197612040-00001. PMID: 786608.
Spada F, Barnes TM, Greive KA. Comparative safety and efficacy of topical mometasone furoate with other topical corticosteroids. Australasian Journal of Dermatology. 2018;59(3):168-74. DOI: 10.1111/ajd.12762. PMID: 29411351.
Radionov VG, Shvariova TI, Bespoludin ED. An experience of use mometazon furoat in the allergic skin diseases. Ukrainian Journal of Dermatology, Venereology, Cosmetology. Ukrainian Journal of Dermatology, Venereology, Cosmetology. 2012;2(45) :61-7. Available at: http://www.vitapol.com.ua/user_files/pdfs/uzdvk/uzd45i12uj212.pdf [in Ukrainian].
Ruzicka T. Methylprednisolone aceponate in eczema and other inflammatory skin disorders – a clinical update. International Journal of Clinical Practice. 2006;60(1):85-92. DOI: 10.1111/j.1368-5031.2005.00754.x. PMID: 16409433.
, Torrelo A. Methylprednisolone aceponate for atopic dermatitis. International Journal of Dermatology. 2017;56(6):691-7. DOI: 10.1111/ijd.13485. PMID: 28258632.
Gupta AK, Chow M. Prednicarbate (Dermatop): profile of a corticosteroid. Journal of Cutaneous Medicine and Surgery. 2004;8(4):244-7. DOI: 10.1007/s10227-004-0120-x. PMID: 16092003.
Okhotnykova EN, Havrylenko TY, Hladush YuY, Yvanova TP, Yakovleva NIu, Mostovenko RV, et al. Effektivnost i bezopasnost sovremennoj naruzhnoj protivovospalitelnoj terapii atopicheskogo dermatita u detej [Efficacy and safety of modern external anti-inflammatory therapy of atopic dermatitis in children]. Klinichna imunolohiia. Alerholohiia. Infektolohiia [Clinical immunology. Allergology. Infectology]. 2016;1:31-7. Available at: https://kiai.com.ua/ua/archive/2016/1/pages-31-37/effektivnost-i-bezopasnost-sovremennoy-naruzhnoy-protivovospalitelnoy-terapii-atopicheskogo-dermatita-u-detey- [in russian].
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.